Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

117.41
+1.371.18%
Post-market: 117.00-0.4100-0.35%19:59 EST
Volume:14.41M
Turnover:1.69B
Market Cap:146.22B
PE:308.97
High:118.42
Open:115.65
Low:114.79
Close:116.04
Loading ...

GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance

Zacks
·
12 Feb

Leerink Adjusts Price Target on Gilead Sciences to $104 From $99

MT Newswires Live
·
12 Feb

RBC Raises Price Target on Gilead Sciences to $90 From $84, Keeps Sector Perform Rating

MT Newswires Live
·
12 Feb

Gilead : Leerink Partners Raises Target Price to $104 From $99

THOMSON REUTERS
·
12 Feb

Gilead price target raised to $110 from $105 at Piper Sandler

TIPRANKS
·
12 Feb

Analysts Conflicted on These Healthcare Names: Edwards Lifesciences (EW), Gilead Sciences (GILD) and Exelixis (EXEL)

TIPRANKS
·
12 Feb

Gilead : Bmo Raises Target Price to $115 From $110

THOMSON REUTERS
·
12 Feb

Gilead Sciences: Balancing Strong HIV Franchise Performance with Cautious Outlook

TIPRANKS
·
12 Feb

BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales

Reuters
·
12 Feb

Gilead Sciences Shares up 4.5% Premarket After Co Forecasts FY25 Profit Above Estimates

THOMSON REUTERS
·
12 Feb

U.S. RESEARCH ROUNDUP-Edison International, Onestream, Vertex Pharmaceuticals

Reuters
·
12 Feb

Gilead Sciences Inc (GILD) Q4 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology Segments

GuruFocus
·
12 Feb

Gilead : Piper Sandler Raises Target Price to $110 From $105

THOMSON REUTERS
·
12 Feb

Gilead Sciences Reports Strong 2024 Financial Performance

TIPRANKS
·
12 Feb

Gilead Sciences: Strong Financial Performance and Promising Future Prospects Justify Buy Rating

TIPRANKS
·
12 Feb

Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
12 Feb